Author

A. C. Vargas

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 2

Signature Assays, Organisms & Methods

Click to filter · or open tag

Research Focus:cell type annotation· 2 Organism:human· 2 Assay:bulk RNA-seq· 1 Research Focus:differential expression· 1 Approach:experimental assay· 1 Research Focus:gene regulatory network inference· 1 Assay:imaging· 1 Approach:statistical model· 1

Frequent Co-Authors

A. E. McCart Reed· 1 shared A. Hasson· 1 shared A. J. Dalley· 1 shared A. J. Gill· 1 shared A. L. Cheah· 1 shared A. Mahar· 1 shared A. R. Green· 1 shared A. Raghavendra· 1 shared

Activity by Year

2019-2021 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 21 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

1 shared paperCancer Biology

A. E. McCart Reed

Mutual co-authors in cluster

Author profile →

2 papers

Recent·Most cited

Epigenome erosion drives neural crest-like phenotypic mimicry in triple-negative breast cancer and other SOX10+ malignancies

J. M. Saunus, X. M. De Luca, K. Northwood, A. Raghavendra, A. Hasson, A. E. McCart Reed, M. Lim, S. Lal, A. C. Vargas, J. R. Kutasovic, A. J. Dalley, M. Miranda, E. Kalaw, P. Kalita-de Croft, I. Gresshoff, , S. R. Lakhani

The paper identifies SOX10 expression in TNBC and other SOX10+ malignancies, linking it to epigenome erosion and neural crest-like phenotypic mimicry through promoter hypomethylation.

bioRxiv · Mar 30, 2021 · PreprintCancer Biology

PD-L1 expression in 522 selected sarcomas with subset analysis of recurrent or metastatic matched samples and association with tumour-infiltrating lymphocytes

A. C. Vargas, F. M. Maclean, L. Sioson, D. Tran, F. Bonar, A. Mahar, A. L. Cheah, P. Russell, P. G. Peter Grimison, L. R. Louise Richardson, A. J. Gill

This study evaluates PD-L1 expression in 522 sarcomas, finding variability across subtypes and demonstrating increased PD-L1 in some metastatic/recurrent samples, suggesting potential for immune checkpoint inhibitor therapy.

bioRxiv · Sep 4, 2019Cancer Biology